For type 2 diabetes, the usual dapagliflozin dose is:

An HbA1c of 7.5% alone does not determine the dose. The choice also depends on your HbA1c target, current drugs such as metformin/insulin/sulfonylureas, kidney function, blood pressure, hydration status, and whether there is heart failure or chronic kidney disease.

Before starting, a clinician should check eGFR/creatinine and volume status. For glucose lowering in type 2 diabetes, dapagliflozin is not recommended when eGFR is below 45 mL/min/1.73 m², because it is less effective; dosing and indication may differ if it is being used for heart failure or CKD rather than primarily HbA1c reduction. The current US prescribing information supports 5 mg daily initially, then 10 mg daily if needed (FDA label).

Key cautions:

So, if this is uncomplicated type 2 diabetes with adequate kidney function, 5 mg once daily is generally the starting dose, with review in roughly 4-12 weeks before considering 10 mg once daily. Please use it only after your prescriber reviews your kidney function and full medication list.

For most adults with type 2 diabetes already taking metformin, dapagliflozin is added rather than replacing metformin:

Example: if someone takes metformin 1,000 mg twice daily and tolerates it, a common regimen is to continue that and add dapagliflozin 5 mg each morning, later increasing dapagliflozin to 10 mg each morning if appropriate. A fixed-dose once-daily extended-release product combining dapagliflozin and metformin is also available in some countries, but separate tablets are often easier when adjusting doses.

Important practical points:

For an HbA1c of 7.5%, the appropriate combination also depends on the person's current metformin dose, eGFR, weight, cardiovascular or kidney disease, and HbA1c target.